|
Drew is a managing director at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Ceula, Complete Genomics, Genoptix, Ophthonix, and TargeGen. Prior to joining Enterprise Partners in 1987, Drew was a physician and entrepreneur. While still a medical student at Northwestern University, he developed a drug delivery device and licensed it to Eli Lilly. Subsequently Drew joined Lilly as consultant while completing his internship at the University of California Irvine. Drew holds a B.S. from Occidental College and an M.D. from Northwestern University. Drew completed his residency in obstetrics and gynecology at the University of California, Irvine, and holds 20 patents in healthcare related products and services including the first and only biochemical test that predicts preterm delivery. The test is available worldwide and has been used by over a million women. Dr. Senyei focuses his philanthropic efforts in education and the arts. He founded Equity in Education at The Bishops School to encourage entrepreneurs to donate stock for educational programs. He is a member of Northwestern University�s board of trustees, he is chairman of the board of UCSD�s Jacobs School of Engineering and is a member of the board of advisors for UCSD�s School of Medicine. Dr. Senyei is on San Diego�s BIOCOM board of directors and also serves as president of the San Diego Opera. In January, 2006, Drew was named one of the Top 100 VC�s in Forbes Magazine�s 2006 Annual Midas List. | 